Dec. 16 at 9:31 PM
$CVAC
The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for
$BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than
$1.25 billion in the long run.